MINDACT: What the Breast Cancer Trial Found

A trial designed to take treatment away

Most cancer trials ask whether adding something helps. MINDACT asked the opposite. Can a test show who can safely skip chemotherapy?

That is called de-escalation, and it is harder to run. Removing a drug needs proof that the harm of removing it stays below an agreed line.

The line here was set in advance. Take the women who looked high risk clinically but low risk on the gene test, and who had no chemotherapy. For them, the lower edge of the 95 percent confidence interval for 5-year survival without distant spread had to reach 92 percent.

How the two risk scores work

Every participant got two assessments, and the trial is built on where they disagree.

Clinical risk came from a modified Adjuvant! Online, which uses tumor size, grade, node status, and receptor status. That is the traditional way of deciding who needs chemotherapy.

Genomic risk came from MammaPrint, a 70-gene signature. It reads gene activity in the tumor tissue and sorts it into low or high risk of distant recurrence. Our page on biomarker testing and precision medicine explains how these panels work.

Women low on both scores got no chemotherapy. Women high on both got it. The interesting group was where the two disagreed. Those women were randomly assigned to follow one score or the other.

Who took part

The ClinicalTrials.gov record, NCT00433589, describes a completed phase 3 trial. It opened in February 2007.

Enrollment ran to July 2011 and reached 6,693 women, across 112 hospitals in nine European countries. Participants were aged 18 to 70. All had invasive breast cancer of stage T1, T2, or operable T3, up to three positive nodes, and no distant spread.

A total of 1,550 women, 23.2 percent of the trial, were high clinical risk and low genomic risk. Everything hinges on that group.

What the first report showed

At 5 years, among the high-clinical, low-genomic women who had no chemotherapy, survival without distant metastasis was 94.7 percent. The 95 percent confidence interval ran from 92.5 to 96.2 percent.

The lower edge, 92.5, sat above the pre-set boundary of 92. The trial met its goal.

Women in the same group who did have chemotherapy did better by 1.5 percentage points. That gap is real, and the design had judged it acceptable in advance.

The authors concluded that roughly 46 percent of women classed as high clinical risk might not need chemotherapy.

What nine years showed

Short follow-up was the obvious weakness of the 2016 report. Hormone receptor-positive breast cancer can return ten years or more after treatment. The 2021 update answers that.

At a median follow-up of 8.7 years, the 5-year figure held at 95.1 percent, with a confidence interval of 93.1 to 96.6.

At 8 years in the randomized group, survival without distant metastasis was 92.0 percent with chemotherapy and 89.4 percent without. The hazard ratio was 0.66, and the gap 2.6 percentage points.

Then the finding that changed practice. In an exploratory analysis of hormone receptor-positive, HER2-negative disease, the benefit depended sharply on age.

In 464 women aged 50 or younger, 8-year survival without distant metastasis was 93.6 percent with chemotherapy and 88.6 percent without: a gap of 5.0 percentage points. In 894 women older than 50, it was 90.2 percent against 90.0 percent: a gap of 0.2 points.

Node status did not change the picture. The gap was 2.5 points in node-negative women and 1.3 points with one to three positive nodes.

Why the age result may not be about chemotherapy

The authors offer a mechanism, and it is worth understanding because it changes what the number means.

Chemotherapy can shut down ovarian function. In a premenopausal woman with a hormone receptor-positive tumor, that removes the estrogen the cancer feeds on. So some of the apparent benefit in younger women may be a hormonal effect reached by a blunt route.

If so, stronger endocrine therapy might give the same protection without chemotherapy. The authors say more study is needed in younger women. Our page on breast cancer covers how receptor status shapes treatment.

What this means in a clinic today

NCI lists MammaPrint alongside OncotypeDX and the Breast Cancer Index. These gene expression tests predict whether cancer will spread or return after surgery. NCI also describes a prognostic stage that folds tumor size, grade, receptor status, HER2, and a gene score into one assessment.

The shift MINDACT delivered is this. A woman with a worrying tumor on traditional criteria can now be told a test may show chemotherapy would add very little. That conversation still needs the numbers: 2.6 points overall at 8 years, near zero above 50, about 5 points below 50.

When to get checked

A gene test is for people who already have a diagnosis. Getting there starts with noticing a change.

NCI lists a lump in or near the breast or under the arm, a thickened or firm area, and a change in a breast's size or shape. It lists nipple discharge that is not milk, and a nipple that flattens or turns. It lists skin that is scaly, swollen, red, darkened, dimpled, or puckered, and swelling with no lump at all.

Most breast changes are not cancer. NCI's point is that early breast cancer often has no symptom at all. That is why screening exists alongside symptom-checking, not instead of it.

What this trial cannot tell you

It was a non-inferiority trial. It was built to show that skipping chemotherapy is not unacceptably worse, not that it is equally good. A real gap in favor of chemotherapy was measured at every timepoint.

The test finds a low-risk group. It does not identify who would benefit most from chemotherapy. That is a different question, and not one MINDACT was built to answer.

The age analysis was exploratory and underpowered. The authors say so themselves. It generates a hypothesis about younger women and does not settle it.

And participants met set criteria: aged 18 to 70, up to three positive nodes, no distant spread. Someone outside those bounds is outside the evidence. Our page on clinical trial vs standard treatment covers how trial findings become routine care.

Sources

• Cardoso F and colleagues, 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer, N Engl J Med 2016 — https://pubmed.ncbi.nlm.nih.gov/27557300/
• Piccart M and colleagues, 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial, Lancet Oncol 2021 — https://pubmed.ncbi.nlm.nih.gov/33721561/
• ClinicalTrials.gov, MINDACT (NCT00433589) — https://clinicaltrials.gov/study/NCT00433589
• NCI, Breast Cancer Prognosis and Survival Rates — https://www.cancer.gov/types/breast/survival
• NCI, Breast Cancer Signs and Symptoms — https://www.cancer.gov/types/breast/symptoms

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.